Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial

Am J Clin Nutr. 2019 Mar 1;109(3):544-553. doi: 10.1093/ajcn/nqy291.

Abstract

Background: Patients with cystic fibrosis (CF) have increased risk of vitamin D deficiency owing to fat malabsorption and other factors. Vitamin D deficiency has been associated with increased risk of pulmonary exacerbations of CF.

Objectives: The primary objective of this study was to examine the impact of a single high-dose bolus of vitamin D3 followed by maintenance treatment given to adults with CF during an acute pulmonary exacerbation on future recurrence of pulmonary exacerbations.

Methods: This was a multicenter, double-blind, placebo-controlled, intent-to-treat clinical trial. Subjects with CF were randomly assigned to oral vitamin D3 given as a single dose of 250,000 International Units (IU) or to placebo within 72 h of hospital admission for an acute pulmonary exacerbation, followed by 50,000 IU of vitamin D3 or an identically matched placebo pill taken orally every other week starting at 3 mo after random assignment. The primary outcome was the composite endpoint of the time to next pulmonary exacerbation or death within 1 y. The secondary outcomes included circulating concentrations of the antimicrobial peptide cathelicidin and recovery of lung function as assessed by the percentage of predicted forced expiratory volume in 1 s (FEV1%).

Results: A total of 91 subjects were enrolled in the study. There were no differences between the vitamin D3 and placebo groups in time to next pulmonary exacerbation or death at 1 y. In addition, there were no differences in serial recovery of lung function after pulmonary exacerbation by FEV1% or in serial concentrations of plasma cathelicidin.

Conclusions: Vitamin D3 initially given at the time of pulmonary exacerbation of CF did not alter the time to the next pulmonary exacerbation, 12-mo mortality, serial lung function, or serial plasma cathelicidin concentrations. This trial was registered at clinicaltrials.gov as NCT01426256.

Keywords: cathelicidin; clinical trial; cystic fibrosis; lung function; nutrition; pulmonary exacerbation; vitamin D.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antimicrobial Cationic Peptides / blood
  • Cathelicidins
  • Cystic Fibrosis / blood
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / immunology*
  • Cystic Fibrosis / physiopathology
  • Dietary Supplements / analysis
  • Double-Blind Method
  • Female
  • Forced Expiratory Volume
  • Humans
  • Immune System / drug effects*
  • Immune System / immunology
  • Lung / drug effects
  • Lung / immunology
  • Lung / physiopathology
  • Male
  • Vitamin D / administration & dosage*
  • Vitamin D Deficiency / blood
  • Vitamin D Deficiency / drug therapy*
  • Vitamin D Deficiency / immunology
  • Vitamin D Deficiency / physiopathology
  • Young Adult

Substances

  • Antimicrobial Cationic Peptides
  • Vitamin D
  • Cathelicidins

Associated data

  • ClinicalTrials.gov/NCT01426256